OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...
Notice convening the Annual General Meeting of AB Electrolux
The shareholders of AB Electrolux (publ), reg. no. 556009-4178 (the "Company"), are hereby given notice of the Annual General Meeting to be held on Wednesday, March 26, 2025, at 4.00 p.m. (CET) at Bio ...